Genomics of Probiotics and Prebiotics
Probiotic microscopic organisms from the Lactobacillus and Bifidobacterium species have a place with the Firmicutes and the Actinobacteria phylum, individually. Lactobacilli are individuals of the lactic acid microscopic organisms (LAB) gathering, an extensively characterized group of microorganisms that age different hexoses into basically lactic acid. Lactobacilli are normally low G + C gram-positive species which are phylogenetically with more than 100 species recorded to date. Bifidobacteria are hetero-fermentative, high G + C content microscopic organisms with around 30 types of bifidobacteria depicted to date. Lactobacilli and bifidobacteria are both autochthonous (normally happening) and allochthonous (transient) inhabitants of the gastrointestinal tract (GIT) when conveyed as probiotic societies. Lactobacilli and bifidobacteria are utilized broadly as probiotics; live smaller scale living microorganisms which, when regulated in sufficient amount to give a medical advantage on the host. Lactobacillus species have for some time been related with the creation of aged nourishments, counting dairy items, vegetables, meat, and sourdough bread. Their referred quick fermentation additionally adds to flavour, surface, and food. The expansion of bifidobacteria to nourishments has been later were intentionally included in light of their announced medical advantages and probiotic properties. In spite of the low predominance of lactobacilli in the GI miniaturized scale biology contrasted with the colonic related bifidobacteria, they speak to a noteworthy part of the microbiota dwelling in the small digestive system. Subsequently, certain strains of Lactobacillus, especially those of human root, have been abused as probiotics. Utilization of probiotics is focused towards carriage of these strains into the intestinal tract; consequently these microbes show properties, for example, bile and acid protection.
In addition, Bifidobacterium and a few lactobacilli have the capacities to age oligosaccharides which are not processed by people and thus can present a development advantage for these gainful microbes in the GIT.
Related Conference of Genomics of Probiotics and Prebiotics
April 27-28, 2026
14th International Conference on COPD Clinical Trials & Lung Care Advances
Paris, Aland Islands
May 14-15, 2026
6th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
June 29-30, 2026
16th International Conference on Pulmonary & Respiratory Medicine
Aix-en-Provence, France
Genomics of Probiotics and Prebiotics Conference Speakers
Recommended Sessions
- Prebiotic Foods
- Applications of probiotics in Aquaculture
- Applications of Probiotics in Health and Diseases
- Biological effects of probiotics
- Common Therapies of Probiotics
- Genomics of Probiotics and Prebiotics
- Health Effects and Applications of Prebiotics
- Mechanisms of Probiotics
- Microbiome and Probiotics
- Prebiotics
- Probiotic Industrial Products
- Probiotic Nutrition
- Probiotics
- Probiotics for Animal Health
- Regulatory perspectives of Probiotics and Prebiotics
- Strains of Probiotics
- Synbiotic
- The Future of Prebiotics and Probiotics
Related Journals
Are you interested in
- Advances in Mechanical Ventilation and Respiratory Support - Pulmonology-2026 (Spain)
- Airway Management Techniques in Critical Care Settings - Pulmonology-2026 (Spain)
- Asthma - Pulmonary Meet 2026 (France)
- Asthma Management: Guidelines and Personalized Therapy - Pulmonology-2026 (Spain)
- Cardiopulmonary Disease - Tuberculosis-2026 (France)
- Chronic Bronchitis - Pulmonary Meet 2026 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Pulmonary Meet 2026 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2026 (France)
- Chronic Obstructive Pulmonary Disease (COPD) Updates - Pulmonology-2026 (Spain)
- Climate Change and Respiratory Diseases - Tuberculosis-2026 (France)
- Critical Care Strategies in Sepsis and Multi-Organ Failure - Pulmonology-2026 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2026 (France)
- Drug-Resistant Tuberculosis: - Tuberculosis-2026 (France)
- Early Detection and Diagnosis - Tuberculosis-2026 (France)
- Epidemiology of TB Disease - Tuberculosis-2026 (France)
- Ethical Dilemmas and Decision-Making in ICU Settings - Pulmonology-2026 (Spain)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2026 (France)
- Immunotherapy and Biologics in Respiratory Diseases - Pulmonology-2026 (Spain)
- Infection Control Measures - Tuberculosis-2026 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2026 (France)
- Innovations in Interventional Pulmonology - Pulmonology-2026 (Spain)
- Integrated Healthcare Approach - Tuberculosis-2026 (France)
- Interstitial Lung Disease (ILD) - Pulmonary Meet 2026 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2026 (France)
- Lung Cancer - Pulmonary Meet 2026 (France)
- Lung Cancer Screening, Diagnosis, and Interventions - Pulmonology-2026 (Spain)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2026 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2026 (France)
- Lung Infection - Tuberculosis-2026 (France)
- Lung Infections: Tuberculosis, Pneumonia, and Beyond - Pulmonology-2026 (Spain)
- Lung Problems - Pulmonary Meet 2026 (France)
- Lung Transplantation - Pulmonary Meet 2026 (France)
- Management of Acute Respiratory Distress Syndrome (ARDS) - Pulmonology-2026 (Spain)
- Multidrug-resistant TB - Tuberculosis-2026 (France)
- Mycobacterial Infections - Tuberculosis-2026 (France)
- Non-Invasive Ventilation in Acute and Chronic Care - Pulmonology-2026 (Spain)
- Nutrition and Tuberculosis - Tuberculosis-2026 (France)
- One Health Approach to TB Control - Tuberculosis-2026 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2026 (France)
- Pediatric Pulmonology and Critical Care Challenges - Pulmonology-2026 (Spain)
- Pediatric Tuberculosis - Tuberculosis-2026 (France)
- Pleural Diseases - Pulmonary Meet 2026 (France)
- Point-of-Care Ultrasound in Critical Care Medicine - Pulmonology-2026 (Spain)
- Post-COVID Pulmonary Complications and Long-Term Care - Pulmonology-2026 (Spain)
- Prevention and Control of Respiratory Diseases - Pulmonary Meet 2026 (France)
- Preventive Therapy - Tuberculosis-2026 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2026 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2026 (France)
- Pulmonary Edema - Tuberculosis-2026 (France)
- Pulmonary Fibrosis and Interstitial Lung Disease - Pulmonology-2026 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2026 (France)
- Pulmonary Hypertension: Diagnosis and Emerging Therapies - Pulmonology-2026 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2026 (France)
- Pulmonary Rehabilitation and Patient-Centered Recovery - Pulmonology-2026 (Spain)
- Pulmonology - Pulmonary Meet 2026 (France)
- Research and Innovation - Tuberculosis-2026 (France)
- Respiratory Disorders - Pulmonary Meet 2026 (France)
- Respiratory Tract Infections - Pulmonary Meet 2026 (France)
- Role of Imaging in Pulmonary Diagnostics and ICU Care - Pulmonology-2026 (Spain)
- Sleep-Disordered Breathing and CPAP Therapies - Pulmonology-2026 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2026 (France)
- TB Clinical Trials - Tuberculosis-2026 (France)
- TB Vaccines - Tuberculosis-2026 (France)
- TB-HIV Co-Infection: - Tuberculosis-2026 (France)
- TB-HIV Co-infections - Tuberculosis-2026 (France)
- Tuberculosis - Pulmonary Meet 2026 (France)
- Tuberculosis in Vulnerable Populations - Tuberculosis-2026 (France)
- Vaccination Programs: - Tuberculosis-2026 (France)
